

PCT #



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0113

Inventors: Yang et al.

Serial No.: 09/700,770

Filing Date: Not yet assigned


Examiner: Not yet assigned

Group Art Unit: Not yet assigned

Title: A Novel Method of Diagnosing,  
Monitoring, and Staging Lung Cancer

I, Kathleen A. Tyrrell, Registration No. 38,350,  
certify that this correspondence is being deposited  
with the U.S. Postal Service as First Class mail  
in an envelope addressed to the Assistant Commissioner  
for Patents, Washington, D.C. 20231.

On this date: July 9, 2001

  
Kathleen A. Tyrrell, Registration No. 38,350

**BOX SEQUENCE**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:


**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

In response to the "Notification to Comply With Requirements  
for Patent Applications Containing Nucleotide Sequence and/or  
Amino Acid Sequence Disclosures" which was included in the Notice  
of Missing Requirements dated May 21, 2001, a response to which  
is due July 21, 2001, enclosed herewith is:

- ( ) Amendment under 1.825;
- (XX) Statement to Support Filing and Submission in Accordance with 37 CFR §§ 1.821 through 1.825;
- ( ) Substitute pages of the Sequence Listing;
- (XX) Substitute copy of the computer readable form of the Sequence Listing;
- (XX) Copy of Notification to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- ( ) Petition for Extension of Time;
- ( ) Other:

The Commissioner is hereby authorized to charge any underpayment associated with this communication or credit any overpayment to Deposit Account No. 50-1619. This sheet is attached in duplicate.

Respectfully submitted,




Kathleen A. Tyrrell  
Registration No. 38,350

Date: July 9, 2001

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/700770	YANG	F DEX-0113

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/US99/10344

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

12 MAY 99

21 MAY 98

DATE MAILED: 21 MAY 2001

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☐ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☒ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☐ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ Other: \_\_\_\_\_

**APPLICANT MUST PROVIDE:**


- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☐ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE  
CALL:**

(703) 308-4216, for Rules interpretation,  
(703) 308-4212, for CRF submission help,  
(703) 287-0200, for PatentIn software help.

Karen Williams

Telephone: 703-305-3688



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0113

Inventors: Yang et al.

Serial No.: 09/700,770

Filing Date: Not yet assigned


Examiner: Not yet assigned

Group Art Unit: Not yet assigned

Title: A Novel Method of Diagnosing,  
Monitoring, and Staging Lung Cancer

I, Kathleen A. Tyrrell, Registration No. 38,350,  
certify that this correspondence is being deposited  
with the U.S. Postal Service as First Class mail  
in an envelope addressed to the Assistant Commissioner  
for Patents, Washington, D.C. 20231.

On this date: July 9, 2001

  
Kathleen A. Tyrrell, Registration No. 38,350

**BOX SEQUENCE**

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE  
WITH 37 CFR §§ 1.821 THROUGH 1.825**

- ( ) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- ( ) I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.

- (XX) I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- ( ) I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- ( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,



Kathleen A. Tyrrell  
Registration No. 38,350

Date: July 9, 2001

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515